Propeller Health announced this week that it was cleared by the FDA to market its platform with medications using GlaxoSmithKline’s Diskus dry powder inhaler.

“Today we’re excited to announce back-to-back FDA clearances that demonstrate our leadership and commitment to a singular goal; moving the field of respiratory health forward,” Propeller Co-Founder and CEO David Van Sickle said in a statement. “510(k) clearance of our platform with inhaler devices from leading global respiratory companies GlaxoSmithKline and Boehringer Ingelheim opens the door for millions of patients to expect and achieve something better in asthma and COPD.”

Propeller Health has now received four clearances by the FDA.